Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA Network (2022) Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP program, Diabetes Care (2022) What causes obesity & overweight?, Eunice Kennedy Shriver National Institute of Child Health and Human Development (2021) Compounding and the FDA: Questions and Answers, Food and Drug Administration (2024) Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes, Reviews in Endocrine and Metabolic Disorders (2022) FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, Food and Drug Administration (2024) Thinking of using a compounding pharmacy
Given that semaglutide can alter gut microbiome composition, probiotic supplementation may provide additional protection
By managing blood sugar levels, semaglutide helps people with type 2 diabetes avoid dangerous spikes in glucose levels, which is important for overall health, including kidney health
Hypoglycemia rates remained low with both drugs
doi:10.1016/j.cmet.2023.11.009 34
Sola-Leyva, A., Pathare, A.D.S., Apostolov, A., et al
